Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Crypto-related stocks plummet again, as AI agents severely impact the industry's growth outlook.

Crypto-related stocks plummet again, as AI agents severely impact the industry's growth outlook.

华尔街见闻华尔街见闻2026/04/09 18:08
Show original
An index tracking Software as a Service (SaaS) stocks fell by 5.5%, with a cumulative decline of nearly 10% this week and an overall decrease of almost 40% since 2026. Regarding individual stocks, Microsoft Corporation fell by 1.5%, Palantir Technologies Inc. dropped 7%, Oracle Corporation decreased 2.8%, Salesforce Inc. was down 3.9%, ServiceNow Inc. dropped 6.4%, and Workday Inc. fell 6%. Expand
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11